Tech Company Financing Transactions
Atea Pharmaceuticals Funding Round
Hercules Capital and Morgan Stanley Bank invested in a $200 million funding round for Atea Pharmaceuticals. The round closed on 11/9/2026.
Transaction Overview
Company Name
Announced On
11/9/2026
Transaction Type
Debt
Amount
$200,000,000
Round
Undisclosed
Investors
Hercules Capital (Lead Investor)
Proceeds Purpose
The credit facility will strengthen Atea Pharmaceuticals' financial position and provide strategic and operational flexibility as the company expands its commercial-related activities in preparation for the potential US launch of its bemnifosbuvir/ruzasvir (BEM/RZR) treatment for chronic hepatitis C virus (HCV), subject to regulatory approval. The financing will also support the advancement of its clinical development programme for hepatitis E virus (HEV). The initial $65 million, together with the company's existing cash and investments, is expected to fund planned operations into mid-2028, while additional milestone-based borrowings could extend its financial runway potentially through profitability.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
125 Summer St.
Boston, MA 02110
USA
Boston, MA 02110
USA
Phone
Website
Email Address
Not Recorded
Overview
Discovering and rapidly advancing transformative antiviral therapies. Atea (Nasdaq: AVIR) is a clinical stage biopharmaceutical company discovering and developing best-in-class therapies to address the unmet medical needs of patients with life-threatening viral diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jean Sommadossi
Chief Financial Officer
Daniel Geffken
Chief Medical Officer
Nathaniel Brown
Executive Vice President
Steven Good
Executive Vice President
Adel Mousa
Executive Vice President
Xiao-Jian Zhou
VP - Bus. Development
John Vavricka
VP - Finance
Wayne Foster
VP - General Counsel
Andrea Corcoran
VP - Operations
Keith Pietropaolo
Browse more venture capital transactions:
Prev: 11/9/2026: Genios AI venture capital transaction
Next: 11/9/2026: Electra Defense venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs